Sublingual Methadone for the Management of Cancer Breakthrough Pain

• Status: Completed
• Trial end date: 2007-01-01
• Target enrollment: 0
• Participant gender: All

Summary

A dose titration protocol for sublingual methadone hydrochloride for the management of cancer-related breakthrough pain to find the optimal dose.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AHS Cancer Control Alberta; Alberta Health Services
• Collaborator: Calgary Health Region
• Treatments: Methadone

Criteria

Inclusion Criteria:

• > 18 years of age

• Experiences episodes of breakthrough pain which respond to opioid therapy

• Controlled baseline pain

• Cognitive status sufficient for accurate completion of assessment form

• Willing to provide written informed consent

• Ability to hold a volume of 1 cc of water under the tongue for 5 minutes

Exclusion Criteria:

• Currently or has received methadone during the previous week

• Recent history of substance abuse

• Severe respiratory impairment or other contraindications to opioids

• Recently received therapies that had the potential to alter pain intensity or response to analgesics

• Symptomatic anemia